Fig. 2From: A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancersComparison of PSMA expression represented as a proportion of DAB (a) between sensitive, partially sensitive and resistant/refractory ovarian tumours and (b) between pre-chemotherapy and post-chemotherapy samples. Lines denote median values, 10th and 90th percentiles, red crosses denote mean valueBack to article page